Cytel, Suvoda Announce Partnership at the Drug Information Association (DIA) 50th Annual Meeting
Alliance will rapidly expand sponsors and CROs access to advanced predictive, implementation, and operations support technologies
Cytel Inc., a leading provider of adaptive trial design software, strategic consulting and clinical research services, and Suvoda LLC, an innovative provider of Interactive Response Technology (IRT) jointly announced a complimentary partnership during the Drug Information Association’s (DIA) annual meeting in San Diego.
Customers will have access to an array of Cytel’s validated predictive analytics and trial implementation support technologies when choosing the Suvoda IRT product.
“We want our customers to get the best possible guidance in the critical areas of randomization and trial supply management. Integrated access to Cytel’s expertise will be invaluable to our clients when designing and conducting the increasingly complex study protocols we are seeing today”, said Jagath Wanninayake, founder & CEO ofSuvoda.
Senior Vice President for Cytel Clinical Research Services, Irving Dark said of the partnership, “The partnership between Cytel and Suvoda underscores our commitment to delivering world‐class statistical software and predictive analytics to improve success rates in drug development. Coupling Suvoda’s cutting‐edge IRT solution with Cytel’s robust software suite will enable sponsors to leverage the combined power of our respective expertise in a seamless and efficient manner.”
The two companies will announce specific capabilities as their integration efforts progress. At DIA, learn more from Cytel and Suvoda representatives at Cytel booth #725.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
